Arteriocyte is now a part of Isto Biologics.
Cleveland, OH, May 2, 2014
Hopkinton, MA, December 6, 2013
Arteriocyte Medical Systems, Inc., applauds CMS for adding Magellan® Bio-Bandage™ as an option for Medicare and Medicaid Patients with chronic wounds.
Cleveland, OH, September 26, 2013
Hopkinton, MA, June 4, 2012
Arteriocyte Awarded BARDA Contract Valued up to $101.1 Million for Advanced Development of Arteriocyte's Magellan™ BioBandageTM for Thermal Radiation Injury.
Arteriocyte Medical Systems, Inc. announced today approval by the U.S. Food and Drug Administration (FDA) to manufacture and distribute the Arteriocyte Medical Systems brand of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan® Platelet Separation System.
Cleveland, OH, April 6, 2012
Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
Cleveland, OH, June 7, 2011
Arteriocyte and the US Army Institute of Surgical Research (USAISR) sign a CRADA to speed development of Cellular Therapies for Orthopaedic Trauma.
Cleveland, OH, January 28, 2011
Arteriocyte announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia (CLI).
Cleveland, OH, May 20, 2009
Arteriocyte Medical Systems announced today a strategic investment in Control Medical Technology, a medical device developer based in Park City, Utah.
Thursday, November 08, 2007
Arteriocyte Medical Systems Forms Strategic Partnership with Medtronic including Acquisition of the Magellan Platelet Rich Plasma Business.
Thursday, October 25, 2007
Arteriocyte, Inc. and DW Healthcare Partners, today announced the formation of Arteriocyte Medical Systems, Inc., launching the company with a $10 million growth capital investment.